Press Releases for SLXP

Press Releases
Salix Pharmaceuticals, Ltd. Completes Sale of 6.325 Million Shares of Common Stock
Salix Pharmaceuticals Secures Additional Intellecutual Property Relating to Rifaximin
Salix Pharmaceuticals Reports 2Q2009 Results Updates Full Year Guidance
StockPreacher.com Issues Trading Outlook for ViroPharma Inc.
Salix Pharmaceuticals to Present at BMO Conference
Salix Pharmaceuticals Announces 2Q2009 Financial Results Conference Call and Webcast
Salix’s Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission from Ulcerative Colitis
Salix's Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission From Ulcerative Colitis
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
Certain Salix Officers and Directors Adopt 10b5-1 Trading Plans for Stock Options That Are Scheduled to Expire During 2010
Salix Pharmaceuticals Reports 1Q2009 Results
Salix Pharmaceuticals to Present at Bank of America and Merrill Lynch Conference
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Salix Pharmaceuticals Announces 1Q2009 Financial Results Conference Call and Webcast
Salix Pharmaceuticals to Present at Cowen Conference
Salix Pharmaceuticals Reports 4Q2008 and FY2008 Results
Salix Announces FDA Complete Response Letter for METOZOLV™ ODT
Salix Pharmaceuticals Announces 4Q2008 and FY2008 Financial Results Conference Call and Webcast
Salix Pharmaceuticals to Present at Roth Conference
Zacks Bull & Bear of the Day Highlights: China Life Insurance, Salix Pharmaceuticals, ArcelorMittal, AK Steel and BHP Billiton
Salix Receives FDA Complete Response Letter for Balsalazide Tablet
Salix Pharmaceuticals Announces New Online Resource Site to Educate Healthcare Providers on Proper Use of Prescription Bowel Cleansing Preparations
Salix In-Licenses Crofelemer from Napo Pharmaceuticals
FDA Extends METOZOLV™ ODT Review Date
Salix Announces Issuance of U.S. Patent for Rifaximin
Salix Pharmaceuticals to Present at Credit Suisse Conference
Salix Pharmaceuticals Reports 3Q2008 Results
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis - Market Wire
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis - Business Wire
Salix Pharmaceuticals Announces 3Q2008 Financial Results Conference Call and Webcast
Zacks Bull and Bear of the Day Highlights: PetMed Express, Salix Pharmaceuticals, Brasil Telecom, Campbell Soup and HDFC Bank
Data Released Today Demonstrate That Mesalamine Granules Maintain Remission in Ulcerative Colitis Patients Who Switch from Another 5-ASA
Data Released Today Demonstrate That Mesalamine Granules Maintain Remission in Ulcerative Colitis Patients Who Switch From Another 5-ASA
Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS)
Rifaximin Demonstrates Highly Statistically Significant Results in Prevention of Hepatic Encephalopathy in Pivotal Phase 3 Study
Salix Commences Patent Infringement Litigation against Novel Laboratories - Sep 8 2008 4:27PM
Salix Pharmaceuticals to Present at Thomas Weisel Partners Conference
Salix Pharmaceuticals Closes Sale of Convertible Notes
Salix Pharmaceuticals Prices Convertible Notes Offering
Salix Pharmaceuticals Announces Proposed Convertible Note Offering
Salix Pharmaceuticals Reports 2Q2008 Results
Salix Pharmaceuticals to Present at Two Investment Conferences During August
Salix Pharmaceuticals Announces 2Q2008 Financial Results Conference Call and Webcast
Salix Initiates Phase 3 For Rifaximin in Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals to Present at UBS Conference - May 27 2008 1:01AM
Balsalazide 3.3 Grams Twice-Daily Shows Significant Improvement in Bowel Function and Some Quality of Life Measures as Early as Week Two - May 26 2008 10:29PM
Salix Presents New Rifaximin Phase IIb Data Demonstrating Significant and Sustained Improvement in Diarrhea-Associated Irritable Bowel Syndrome (D-IBS) - May 27 2008 12:58AM
Balsalazide 3.3 Grams Twice-Daily Shows Significant Improvement in Bowel Function and Some Quality of Life Measures as Early as Week Two - Jun 2 2008 4:13AM
Balsalazide 3.3 Grams Twice-Daily Shows Significant Improvement in Bowel Function and Some Quality of Life Measures as Early as Week Two - May 27 2008 12:58AM
Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet - May 26 2008 10:28PM
Salix Commences Patent Infringement Litigation Against Novel Laboratories - May 27 2008 12:53AM
Salix Pharmaceuticals to Present at Bank of America Conference - Jun 2 2008 4:13AM
Salix Pharmaceuticals Reports 1Q2008 Results - Jun 2 2008 4:13AM
Salix Pharmaceuticals Announces 1Q2008 Financial Results Conference Call and Web Cast
Salix Receives Purported Notice of Paragraph IV Certification Against Patent for MOVIPREP(R)